Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial

and the NORDIC IIHTT Study Group

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective: To characterize the phenotype, headache-related disability, medical co-morbidities, use of symptomatic headache medications, and headache response to study interventions in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Methods: Patients with untreated IIH and mild vision loss enrolled in the IIHTT and randomized to acetazolamide (ACZ) and weight loss or placebo (PLB) and weight loss had prospective assessment of headache disability using the Headache Impact Test-6 (HIT-6) questionnaire. Subjects with headache at the baseline visit were assigned a headache phenotype using the International Classification for Headache Disorders version 3 beta (ICHD-3b). Medication overuse was determined using the participants' reported medication use for the preceding month and ICHD-3b thresholds for diagnosing medication overuse headache. We investigated relationships between headache disability and various other clinical characteristics at baseline and at 6 months. Results: Headache was present in 139 (84%) of the 165 enrollees at baseline. The most common headache phenotypes were migraine (52%), tension-type headache (22%), probable migraine (16%), and probable tension-type headache (4%). Fifty-one (37%) participants overused symptomatic medications at baseline, most frequently simple analgesics. A similar amount of improvement in the adjusted mean (± standard error) HIT-6 score occurred in the ACZ (–9.56 ± 1.05) and PLB groups (–9.11 ± 1.14) at 6 months (group difference −0.45, 95% CI −3.50 to 2.60, P =.77). Headache disability did not correlate with any of the studies, variables of interest, which included: the lumbar puncture opening pressure at baseline or at 6 months, body mass index, the amount of weight lost, papilledema grade, perimetric mean deviation, or the use of hormonal contraception. Headache disability was significantly associated with patient-reported quality of life in the physical, mental, and visual domains. Conclusions: Headache was common, of varied character, disabling, and associated with poorer quality of life in our cohort of patients with mild visual impairment. The lack of correlation between headache disability and cerebrospinal fluid (CSF) pressure at baseline and at the end of the randomized phase of the study implies that headache in IIH may be related to factors other than intracranial hypertension, and that specific headache treatment is needed in addition to therapies directed at lowering CSF pressure.

Original languageEnglish (US)
Pages (from-to)1195-1205
Number of pages11
JournalHeadache
Volume57
Issue number8
DOIs
StatePublished - Sep 1 2017

Fingerprint

Pseudotumor Cerebri
Headache
Therapeutics
Cerebrospinal Fluid Pressure
Tension-Type Headache
Headache Disorders
Acetazolamide
Migraine Disorders
Phenotype
Secondary Headache Disorders
Weight Loss
Placebos
Quality of Life
Papilledema
Spinal Puncture
Intracranial Hypertension

Keywords

  • headache
  • Headache Impact Test-6
  • idiopathic intracranial hypertension
  • medication overuse

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Headache in Idiopathic Intracranial Hypertension : Findings From the Idiopathic Intracranial Hypertension Treatment Trial. / and the NORDIC IIHTT Study Group.

In: Headache, Vol. 57, No. 8, 01.09.2017, p. 1195-1205.

Research output: Contribution to journalArticle

@article{f248ddebc3a54f39af952289653666fc,
title = "Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial",
abstract = "Objective: To characterize the phenotype, headache-related disability, medical co-morbidities, use of symptomatic headache medications, and headache response to study interventions in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Methods: Patients with untreated IIH and mild vision loss enrolled in the IIHTT and randomized to acetazolamide (ACZ) and weight loss or placebo (PLB) and weight loss had prospective assessment of headache disability using the Headache Impact Test-6 (HIT-6) questionnaire. Subjects with headache at the baseline visit were assigned a headache phenotype using the International Classification for Headache Disorders version 3 beta (ICHD-3b). Medication overuse was determined using the participants' reported medication use for the preceding month and ICHD-3b thresholds for diagnosing medication overuse headache. We investigated relationships between headache disability and various other clinical characteristics at baseline and at 6 months. Results: Headache was present in 139 (84{\%}) of the 165 enrollees at baseline. The most common headache phenotypes were migraine (52{\%}), tension-type headache (22{\%}), probable migraine (16{\%}), and probable tension-type headache (4{\%}). Fifty-one (37{\%}) participants overused symptomatic medications at baseline, most frequently simple analgesics. A similar amount of improvement in the adjusted mean (± standard error) HIT-6 score occurred in the ACZ (–9.56 ± 1.05) and PLB groups (–9.11 ± 1.14) at 6 months (group difference −0.45, 95{\%} CI −3.50 to 2.60, P =.77). Headache disability did not correlate with any of the studies, variables of interest, which included: the lumbar puncture opening pressure at baseline or at 6 months, body mass index, the amount of weight lost, papilledema grade, perimetric mean deviation, or the use of hormonal contraception. Headache disability was significantly associated with patient-reported quality of life in the physical, mental, and visual domains. Conclusions: Headache was common, of varied character, disabling, and associated with poorer quality of life in our cohort of patients with mild visual impairment. The lack of correlation between headache disability and cerebrospinal fluid (CSF) pressure at baseline and at the end of the randomized phase of the study implies that headache in IIH may be related to factors other than intracranial hypertension, and that specific headache treatment is needed in addition to therapies directed at lowering CSF pressure.",
keywords = "headache, Headache Impact Test-6, idiopathic intracranial hypertension, medication overuse",
author = "{and the NORDIC IIHTT Study Group} and Friedman, {Deborah I.} and Quiros, {Peter A.} and Subramanian, {Prem S.} and Mejico, {Luis J.} and Shan Gao and Michael McDermott and Michael Wall",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/head.13153",
language = "English (US)",
volume = "57",
pages = "1195--1205",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Headache in Idiopathic Intracranial Hypertension

T2 - Findings From the Idiopathic Intracranial Hypertension Treatment Trial

AU - and the NORDIC IIHTT Study Group

AU - Friedman, Deborah I.

AU - Quiros, Peter A.

AU - Subramanian, Prem S.

AU - Mejico, Luis J.

AU - Gao, Shan

AU - McDermott, Michael

AU - Wall, Michael

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective: To characterize the phenotype, headache-related disability, medical co-morbidities, use of symptomatic headache medications, and headache response to study interventions in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Methods: Patients with untreated IIH and mild vision loss enrolled in the IIHTT and randomized to acetazolamide (ACZ) and weight loss or placebo (PLB) and weight loss had prospective assessment of headache disability using the Headache Impact Test-6 (HIT-6) questionnaire. Subjects with headache at the baseline visit were assigned a headache phenotype using the International Classification for Headache Disorders version 3 beta (ICHD-3b). Medication overuse was determined using the participants' reported medication use for the preceding month and ICHD-3b thresholds for diagnosing medication overuse headache. We investigated relationships between headache disability and various other clinical characteristics at baseline and at 6 months. Results: Headache was present in 139 (84%) of the 165 enrollees at baseline. The most common headache phenotypes were migraine (52%), tension-type headache (22%), probable migraine (16%), and probable tension-type headache (4%). Fifty-one (37%) participants overused symptomatic medications at baseline, most frequently simple analgesics. A similar amount of improvement in the adjusted mean (± standard error) HIT-6 score occurred in the ACZ (–9.56 ± 1.05) and PLB groups (–9.11 ± 1.14) at 6 months (group difference −0.45, 95% CI −3.50 to 2.60, P =.77). Headache disability did not correlate with any of the studies, variables of interest, which included: the lumbar puncture opening pressure at baseline or at 6 months, body mass index, the amount of weight lost, papilledema grade, perimetric mean deviation, or the use of hormonal contraception. Headache disability was significantly associated with patient-reported quality of life in the physical, mental, and visual domains. Conclusions: Headache was common, of varied character, disabling, and associated with poorer quality of life in our cohort of patients with mild visual impairment. The lack of correlation between headache disability and cerebrospinal fluid (CSF) pressure at baseline and at the end of the randomized phase of the study implies that headache in IIH may be related to factors other than intracranial hypertension, and that specific headache treatment is needed in addition to therapies directed at lowering CSF pressure.

AB - Objective: To characterize the phenotype, headache-related disability, medical co-morbidities, use of symptomatic headache medications, and headache response to study interventions in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Methods: Patients with untreated IIH and mild vision loss enrolled in the IIHTT and randomized to acetazolamide (ACZ) and weight loss or placebo (PLB) and weight loss had prospective assessment of headache disability using the Headache Impact Test-6 (HIT-6) questionnaire. Subjects with headache at the baseline visit were assigned a headache phenotype using the International Classification for Headache Disorders version 3 beta (ICHD-3b). Medication overuse was determined using the participants' reported medication use for the preceding month and ICHD-3b thresholds for diagnosing medication overuse headache. We investigated relationships between headache disability and various other clinical characteristics at baseline and at 6 months. Results: Headache was present in 139 (84%) of the 165 enrollees at baseline. The most common headache phenotypes were migraine (52%), tension-type headache (22%), probable migraine (16%), and probable tension-type headache (4%). Fifty-one (37%) participants overused symptomatic medications at baseline, most frequently simple analgesics. A similar amount of improvement in the adjusted mean (± standard error) HIT-6 score occurred in the ACZ (–9.56 ± 1.05) and PLB groups (–9.11 ± 1.14) at 6 months (group difference −0.45, 95% CI −3.50 to 2.60, P =.77). Headache disability did not correlate with any of the studies, variables of interest, which included: the lumbar puncture opening pressure at baseline or at 6 months, body mass index, the amount of weight lost, papilledema grade, perimetric mean deviation, or the use of hormonal contraception. Headache disability was significantly associated with patient-reported quality of life in the physical, mental, and visual domains. Conclusions: Headache was common, of varied character, disabling, and associated with poorer quality of life in our cohort of patients with mild visual impairment. The lack of correlation between headache disability and cerebrospinal fluid (CSF) pressure at baseline and at the end of the randomized phase of the study implies that headache in IIH may be related to factors other than intracranial hypertension, and that specific headache treatment is needed in addition to therapies directed at lowering CSF pressure.

KW - headache

KW - Headache Impact Test-6

KW - idiopathic intracranial hypertension

KW - medication overuse

UR - http://www.scopus.com/inward/record.url?scp=85026424601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026424601&partnerID=8YFLogxK

U2 - 10.1111/head.13153

DO - 10.1111/head.13153

M3 - Article

C2 - 28752894

AN - SCOPUS:85026424601

VL - 57

SP - 1195

EP - 1205

JO - Headache

JF - Headache

SN - 0017-8748

IS - 8

ER -